Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : TATRADER GIZZARD STUDY--Stocks 12.00 or Less..... -- Ignore unavailable to you. Want to Upgrade?

To: J.F. who wrote (56338)	9/19/2006 4:54:51 PM
From: J.F.	Respond to of 59879

THLD update DJ Threshold Pharma Chief Medical Officer Resigns >THLD NEWSWIRE Threshold Pharmaceuticals Inc.'s (THLD) Chief Medical Officer Alan Colowick resigned, effective Oct. 13. Colowick will then become a consultant to Threshold and a member of its scientific advisory board. Colowick joined the Redwood City, Calif., company in January 2005. Medical aspects of Colowick's responsibilities will be managed on an interim basis by Michael Brawer, who joined Threshold as a member of the management team earlier this year. Threshold continues to expect top-line results later in 2006 from a Phase III trial of glufosfamide as a pancreatic cancer treatment, as well as top-line results from a Phase II 2 trial of glufosfamide in combination with gemcitabine for treatment of pancreatic cancer. It also continues to expect to begin further glufosfamide trials for several other cancers later this year.